Anthony J. Olszanski, MD, RPh, Joins Journal of the National Comprehensive Cancer Network Editorial Board

Anthony J. Olszanski, MD, RPh. Dr. Olszanski is joined on the board by faculty from such institutions as Harvard Medical School, the Stanford Cancer Institute, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and MD Anderson Cancer Center.

PHILADELPHIA (August 7, 2018) – Anthony J. Olszanski, MD, RPh, vice chair of the Department of Hematology/Oncology and director of the Early Drug Development Phase 1 Program at Fox Chase Cancer Center, has been named an associate editor of JNCCN—Journal of the National Comprehensive Cancer Network.  

JNCCN recently restructured its executive editorial board and conducted an extensive national search for eight new associate editors. The journal invited accomplished health services researchers from various NCCN Member Institutions to help oversee content. Olszanski is joined on the board by faculty from such institutions as Harvard Medical School, the Stanford Cancer Institute, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and MD Anderson Cancer Center.

The journal’s expanding focus on original research is led by editor-in-chief Margaret Tempero, MD, Professor of Medicine and Director of the UCSF Pancreas Center at UCSF Helen Diller Family Comprehensive Cancer Center. This vision has resulted in an all-time high impact factor for the journal. According to InCites Journal Citation Report data from Clarivate Analytics, articles from JNCCN were cited 5,143 times in 2017, resulting in an impact factor of 6.471 for the year, which places it in the top quartile for all oncology journals.

JNCCN studies have recently been featured in The Wall Street Journal, U.S. News & World Report, Physician’s Weekly, Everyday Health, and numerous other outlets. Studies have featured topics such as: breast cancer survivor mammogram rates, the “weekend effect” on emergency colorectal cancer surgery, and the importance of communication around end-of-life care. Every issue of JNCCN also includes the publication of a recently updated edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).

JNCCN publishes 13 issues every year, with select content available for free online at JNCCN.org for three months after publication. NCCN Guidelines Panel Chairs also serve as members of JNCCN’s Guidelines Editorial Board.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text